PMID- 23245688
OWN - NLM
STAT- MEDLINE
DCOM- 20131018
LR  - 20220311
IS  - 1618-0372 (Electronic)
IS  - 0065-1281 (Linking)
VI  - 115
IP  - 5
DP  - 2013 Jun
TI  - Down-regulation of human leukocyte antigen class I (HLA-I) is associated with 
      poor prognosis in patients with clear cell renal cell carcinoma.
PG  - 470-4
LID - S0065-1281(12)00166-3 [pii]
LID - 10.1016/j.acthis.2012.11.002 [doi]
AB  - Human leukocyte antigen class I (HLA-I) molecules are transmembrane glycoproteins 
      that have been reported to be down-regulated in multiple types of human 
      malignancies, including clear cell renal cell carcinoma (CCRCC). However, only 
      one study has investigated its prognostic value in CCRCC. In the present study, 
      HLA-I protein expression was analyzed in 120 archived, paraffin-embedded CCRCC 
      samples and 10 adjacent normal tissues using immunohistochemistry. The 
      correlation between HLA-I expression and clinicopathological factors was 
      evaluated by the chi(2) test. Patients' overall survival was analyzed by the 
      Kaplan-Meier method. HLA-I down-regulation was observed in 38.3% (46/120) of 
      renal tumor samples, but only in 10% (1/10) of adjacent normal tissues. 
      Statistical analysis showed a significant correlation of HLA-I expression with 
      TNM stage, lymph node metastasis, and Fuhrman grade. Patients with tumors 
      displaying down-regulation of HLA-I showed significantly shorter overall survival 
      (P=0.021, log-rank test). More importantly, multivariate analysis indicated that 
      down-regulation of HLA-I was an independent prognostic factor for CCRCC patients 
      (P=0.033). Overall, our data suggest that HLA-I down-regulation is associated 
      with tumor progression and a poor prognosis in CCRCC patients, and emphasize the 
      importance of HLA-I in natural and therapeutic immune surveillance of patients 
      with CCRCC.
CI  - Copyright (c) 2012 Elsevier GmbH. All rights reserved.
FAU - Yuan, Jinyang
AU  - Yuan J
AD  - Department of Urology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Liu, Sulai
AU  - Liu S
FAU - Yu, Qiuxia
AU  - Yu Q
FAU - Lin, Yang
AU  - Lin Y
FAU - Bi, Yunke
AU  - Bi Y
FAU - Wang, Yi
AU  - Wang Y
FAU - An, Ruihua
AU  - An R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121212
PL  - Germany
TA  - Acta Histochem
JT  - Acta histochemica
JID - 0370320
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Renal Cell/*diagnosis/metabolism/mortality
MH  - China/epidemiology
MH  - *Down-Regulation
MH  - Female
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*diagnosis/metabolism/mortality
MH  - Lymph Nodes/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Rate
MH  - Young Adult
EDAT- 2012/12/19 06:00
MHDA- 2013/10/19 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/10/01 00:00 [received]
PHST- 2012/10/31 00:00 [revised]
PHST- 2012/11/01 00:00 [accepted]
PHST- 2012/12/19 06:00 [entrez]
PHST- 2012/12/19 06:00 [pubmed]
PHST- 2013/10/19 06:00 [medline]
AID - S0065-1281(12)00166-3 [pii]
AID - 10.1016/j.acthis.2012.11.002 [doi]
PST - ppublish
SO  - Acta Histochem. 2013 Jun;115(5):470-4. doi: 10.1016/j.acthis.2012.11.002. Epub 
      2012 Dec 12.